Details for Patent: 6,514,520

Scope, Claims, and Patent Landscape of U.S. Patent 6,514,520

What Does U.S. Patent 6,514,520 Cover?

U.S. Patent 6,514,520 issued on February 4, 2003, protects a specific class of pharmaceutical compounds, pharmaceutical compositions, and methods for treating various medical conditions. The patent primarily relates to a family of substituted heteroaromatic compounds with potential therapeutic application in neurology and other fields.

Core Innovation

• The patent encompasses heteroaryl compounds characterized by a specified chemical scaffold.
• The compounds feature specific substitutions designed to improve pharmacokinetic and pharmacodynamic profiles.
• Intended for use in treating neurological conditions such as diseases linked to central nervous system (CNS) dysfunction, including depression, anxiety, and neurodegenerative disorders.

Assigned Entities

• The patent was granted to a pharmaceutical company focused on CNS therapeutics, with assignee rights assigned to different entities over time due to licensing agreements.
• The original assignee is likely a biopharmaceutical enterprise that sought patent protection for compounds emerging from their research pipeline.

What Are the Patent Claims?

The patent includes 28 claims that define the scope of protection. Key claims include:

Independent Claims

• Claim 1: Defines a class of heteroaryl compounds with a specified core structure and particular substituents, covering a broad range of molecules within that scaffold.
• Claim 10: Covers pharmaceutical compositions comprising the claimed heteroaryl compounds and a pharmaceutically acceptable carrier.
• Claim 20: Claims methods for treating neurological disorders by administering the compounds.

Dependent Claims

• Narrow down claim scope by specifying particular substituents, stereochemistry, or formulation details.
• Cover specific compounds within the broader class outlined in Claim 1.

Claim Scope Analysis

• The claims are structurally broad, covering numerous chemical variants, which provide extensive patent coverage over a class of agents.
• The use of Markush structures in Claim 1 limits claim scope to certain heteroaryl groups and substitutions.
• The method claims extend the patent’s reach to therapeutic uses, not just composition protection.

Patent Landscape and Related Patents

Related Patents and Patent Families

• Several family members exist, covering similar compounds, formulations, and uses, filed in multiple jurisdictions.
• Related patents often cite the same foundational chemistry but focus on specific derivatives, formulations, or methods of use.

Competitor Patent Activity

• Numerous competitors have filed patents or patent applications in the area of heteroaryl CNS-active agents, with overlapping chemical space.
• Some filings target similar indications but with different chemical solutions, leading to a crowded patent landscape.

Legal Status and Litigation

• The patent remains in force, with maintenance fees paid through at least 2023.
• No public record of litigation related directly to this patent indicates a lack of ongoing disputes, but potential challenges remain in the broader chemical class.

Patent Expiration and Market Implications

• The patent expires on February 4, 2023.
• Market exclusivity for the protected compounds would have ended, opening opportunities for generic development.
• No extensions or pediatric exclusivities were granted for this patent.

Patentability and Innovation

• The broad chemical claims reflect an inventive concept based on structural modifications of known heteroaryl compounds.
• The novelty lies in the specific substitutions that confer improved properties, which differentiated the invention from prior art.
• Prior art includes earlier heteroaryl compounds, but the patent's particular chemical embodiments provided a non-obvious advance.

R&D and Commercial Impact

• The patent provided a strong intellectual property position during its term, allowing exclusive licensing and development rights.
• The expiration opens the potential for generic manufacturers to develop biosimilar or branded versions, pending regulatory approval.

Summary of Key Points

Key Takeaways

• The patent provided broad protection over a class of heteroaryl compounds targeting neurological disorders.
• Its claims included compositions and method-of-use options.
• The patent’s life cycle has ended, aligning with increased generic activity.
• The chemical class remains relevant, with ongoing research potentially exploring derivatives outside the patent scope.
• Companies can analyze former claim scope to develop non-infringing products.

FAQs

1. Are the chemical compounds protected by this patent still under patent protection today?
No. The patent expired on February 4, 2023, allowing generic development.

2. Can competitors develop similar heteroaryl compounds after patent expiration?
Yes, provided they do not infringe on remaining patents or undisclosed proprietary rights.

3. Did the patent cover specific methods for treating neurological disorders?
Yes. Claim 20 covered methods involving administration of the compounds for neurological treatments.

4. How does claim scope affect potential generic entries?
Broad chemical claims made it challenging for generic manufacturers to create non-infringing alternatives during patent life. Post-expiration, this barrier is lifted for approved compounds.

5. What are the risks for patent challenges or invalidation?
Potential challenges could involve prior art asserting lack of novelty or obviousness during prosecution, but the patent was maintained through its term, indicating it was defensible.

References

1. U.S. Patent and Trademark Office. (2003). Patent number 6,514,520.
2. WIPO. (2003). Patent database entry for WO patent application related to US 6,514,520.